Back to Search Start Over

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

Authors :
Shinsuke Shiotsu
Yusuke Chihara
Akihiro Yoshimura
Yutaka Kubota
Koichi Takayama
Nobuyo Tamiya
Yoshiko Kaneko
Takayuki Takeda
Keiko Tanimura
Soichi Hirai
Tadaaki Yamada
Taishi Harada
Kazuki Hirose
Toshiaki Kikuchi
Junji Uchino
Satoshi Watanabe
Yuki Katayama
Source :
Cancer Medicine, Vol 8, Iss 4, Pp 1521-1529 (2019), Cancer Medicine
Publication Year :
2019
Publisher :
Wiley, 2019.

Abstract

Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with NSCLC with EGFR mutations who exhibit clinical outcomes that require treatment with immune checkpoint inhibitors (ICIs). Therefore, to identify eligible cases to treat with ICIs, we retrospectively analyzed the correlation between clinical features and the efficacy of ICIs in patients with EGFR mutations. Patients and Methods We retrospectively analyzed patients with advanced NSCLC harboring EGFR mutations who were treated with ICIs after developing resistance to EGFR‐TKIs between February 2016 and April 2018 at 6 institutions in Japan. The association between clinical outcomes and the efficacy of ICIs was investigated. Results We enrolled 27 patients who harbored EGFR‐activating mutations. The objective response and disease control rates were higher in patients with uncommon EGFR mutations than in those with common EGFR mutations (71% vs 35.7% and 57% vs 7%, P = 0.14 and P

Details

Language :
English
ISSN :
20457634
Volume :
8
Issue :
4
Database :
OpenAIRE
Journal :
Cancer Medicine
Accession number :
edsair.doi.dedup.....5d5b4bcf9b850b44ed1afbab6ce8bae2